Speciality Medicines IPO Opens For Subscription Today
- By Kotak News Desk
- 20 Mar 2026 at 10:25 AM IST
- Market News
- 4m

Speciality Medicines IPO opens on 20 March and closes on 24 March, with a price band of ₹117–124 per share.
Speciality Medicines initial public offering (IPO) opens for subscription on Friday, 20 March. The company plans to raise about ₹29 crore through a fully fresh issue. The offer will close on 24 March. Shares are scheduled to list on the BSE SME platform on 30 March. The price band has been fixed at ₹117–124 per share.
Other Key IPO Details
Here are the other key details of the Speciality Medicines IPO:
Face Value | ₹10 per share |
Qualified Institutional Buyers (QIBs) shares | Not more than 2% of the issue |
Retail Shares | Not less than 49% of the issue |
Non-Intitutional Investors (NIIs) Shares | Not less than 49% of the issue |
Business Model And Operations
Incorporated in 2021, Speciality Medicines operates in the speciality pharma segment. The company focuses on the marketing and distribution of high-value formulations used in chronic and complex treatments. Its portfolio includes:
- Injectables
- Inhalers
- Ophthalmic products
- Oral formulations
The company follows a dual model. It undertakes contract manufacturing for overseas markets while also distributing sourced speciality pharma products. The company has a presence in more than 35 countries and operates across over 20 states in India.
Also Read - Central Bank Faces ₹1.44 Lakh Crore Bad Loans, Initiates 4,903 Recovery Cases
Use Of Proceeds
The IPO proceeds will be deployed across multiple areas:
- Setting up a new research and development (R&D) centre in Gujarat
- Funding international product registrations
- Supporting marketing activities
- Meeting working capital needs
The research and development investment comes as the company looks to scale its product pipeline and expand overseas registrations.
Sources:
The Economic Times
India IPO
Chittorgarh
This article is for informational purposes only and does not constitute financial advice. It is not produced by the desk of the Kotak Securities Research Team, nor is it a report published by the Kotak Securities Research Team. The information presented is compiled from several secondary sources available on the internet and may change over time. Investors should conduct their own research and consult with financial professionals before making any investment decisions. Read the full disclaimer here.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing. Brokerage will not exceed SEBI prescribed limit. The securities are quoted as an example and not as a recommendation. SEBI Registration No-INZ000200137 Member Id NSE-08081; BSE-673; MSE-1024, MCX-56285, NCDEX-1262.

Kotak News Desk brings you latest updates, expert insights, and market-ready ideas - helping you stay informed and invest smarter.
Connect on: Linkedin
0 people liked this article.




